There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > COLUMN
COLUMN
-
Science without Works Is Dead
June 4, 2012
-
Social Networking in Japan’s Pharmaceutical Industry
May 1, 2012
-
The Eight Characteristics of a Great Leader
April 2, 2012
-
Maurer’s Healthcare Insight (143)
March 26, 2012
-
Maurer’s Healthcare Insight (142)
February 27, 2012
-
Maurer’s Healthcare Insight (141)
January 30, 2012
-
Maurer’s Healthcare Insight (140)
December 26, 2011
-
Maurer’s Healthcare Insight (139)
December 12, 2011
-
Maurer’s Healthcare Insight (138)
November 21, 2011
-
Maurer’s Healthcare Insight(137)
October 17, 2011
-
Maurer’s Healthcare Insight (136)
September 12, 2011
-
Maurer's Healthcare Insight (135)
August 15, 2011
-
Maurer's Healthcare Insight (134)
August 1, 2011
-
Maurer's Healthcare Insight (133)
July 11, 2011
-
Maurer's Healthcare Insight (132)
May 30, 2011
-
Maurer's Healthcare Insight (131)
April 18, 2011
-
Maurer's Healthcare Insight (130)
January 24, 2011
-
Maurer's Healthcare Insight (129)
January 3, 2011
-
Maurer's Healthcare Insight (128)
December 13, 2010
-
Maurer's Healthcare Insight (127)
November 29, 2010
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…